18:02:59 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-04-03 Årsstämma 2025
2025-02-26 Bokslutskommuniké 2024
2024-08-28 Kvartalsrapport 2024-Q2
2024-05-01 X-dag ordinarie utdelning NSIS B 2.00 DKK
2024-04-30 Årsstämma 2024
2024-03-04 Extra Bolagsstämma 2024
2024-02-08 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-10-13 X-dag bonusutdelning NSIS B 4.2
2023-08-09 Kvartalsrapport 2023-Q2
2023-04-26 Kvartalsrapport 2023-Q1
2023-03-30 Extra Bolagsstämma 2023
2023-03-03 X-dag ordinarie utdelning NSIS B 6.00 DKK
2023-03-02 Årsstämma 2023
2023-01-26 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-08-11 Kvartalsrapport 2022-Q2
2022-04-27 Kvartalsrapport 2022-Q1
2022-03-17 X-dag ordinarie utdelning NSIS B 5.50 DKK
2022-03-16 Årsstämma 2022
2022-02-01 Bokslutskommuniké 2021
2021-10-27 Kvartalsrapport 2021-Q3
2021-08-12 Kvartalsrapport 2021-Q2
2021-04-27 Kvartalsrapport 2021-Q1
2021-03-12 X-dag ordinarie utdelning NSIS B 5.25 DKK
2021-03-11 Årsstämma 2021
2021-02-02 Bokslutskommuniké 2020
2020-10-21 Kvartalsrapport 2020-Q3
2020-08-12 Kvartalsrapport 2020-Q2
2020-04-29 Kvartalsrapport 2020-Q1
2020-02-27 X-dag ordinarie utdelning NSIS B 5.25 DKK
2020-02-26 Årsstämma 2020
2020-01-23 Bokslutskommuniké 2019
2019-10-23 Kvartalsrapport 2019-Q3
2019-08-08 Kvartalsrapport 2019-Q2
2019-04-24 Kvartalsrapport 2019-Q1
2019-02-28 X-dag ordinarie utdelning NSIS B 5.00 DKK
2019-02-27 Årsstämma 2019
2019-01-24 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-08-10 Kvartalsrapport 2018-Q2
2018-04-25 Kvartalsrapport 2018-Q1
2018-03-14 X-dag ordinarie utdelning NSIS B 4.50 DKK
2018-03-13 Årsstämma 2018
2018-02-07 Bokslutskommuniké 2017
2017-10-25 Kvartalsrapport 2017-Q3
2017-08-11 Kvartalsrapport 2017-Q2
2017-04-26 Kvartalsrapport 2017-Q1
2017-02-23 X-dag ordinarie utdelning NSIS B 4.00 DKK
2017-02-22 Årsstämma 2017
2017-01-18 Bokslutskommuniké 2016
2016-10-26 Kvartalsrapport 2016-Q3
2016-08-10 Kvartalsrapport 2016-Q2
2016-04-20 Kvartalsrapport 2016-Q1
2016-02-25 X-dag ordinarie utdelning NSIS B 3.50 DKK
2016-02-24 Årsstämma 2016
2016-01-19 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-08-06 Kvartalsrapport 2015-Q2
2015-04-23 Kvartalsrapport 2015-Q1
2015-02-26 X-dag ordinarie utdelning NSIS B 3.00 DKK
2015-02-25 Årsstämma 2015
2015-01-20 Bokslutskommuniké 2014
2014-10-23 Kvartalsrapport 2014-Q3
2014-08-14 Kvartalsrapport 2014-Q2
2014-04-24 Kvartalsrapport 2014-Q1
2014-02-27 X-dag ordinarie utdelning NSIS B 2.50 DKK
2014-02-26 Årsstämma 2014
2014-01-21 Bokslutskommuniké 2013
2013-10-25 Kvartalsrapport 2013-Q3
2013-08-09 Kvartalsrapport 2013-Q2
2013-04-25 Kvartalsrapport 2013-Q1
2013-03-01 X-dag ordinarie utdelning NSIS B 2.20 DKK
2013-02-28 Årsstämma 2013
2012-10-25 Kvartalsrapport 2012-Q3
2012-08-16 Kvartalsrapport 2012-Q2
2012-04-25 Kvartalsrapport 2012-Q1
2012-03-01 X-dag ordinarie utdelning NSIS B 1.90 DKK
2012-02-29 Årsstämma 2012
2012-01-19 Bokslutskommuniké 2011
2011-11-28 Split NSIS B 1:5
2011-10-28 Kvartalsrapport 2011-Q3
2011-08-11 Kvartalsrapport 2011-Q2
2011-04-29 Kvartalsrapport 2011-Q1
2011-03-03 X-dag ordinarie utdelning NSIS B 8.00 DKK
2011-03-02 Årsstämma 2011
2011-01-21 Bokslutskommuniké 2010
2010-10-28 Kvartalsrapport 2010-Q3
2010-08-12 Kvartalsrapport 2010-Q2
2010-04-29 Kvartalsrapport 2010-Q1
2010-03-04 X-dag ordinarie utdelning NSIS B 5.75 DKK
2010-03-03 Årsstämma 2010
2009-03-05 X-dag ordinarie utdelning NSIS B 5.25 DKK
2008-03-06 X-dag ordinarie utdelning NSIS B 5.00 DKK
2007-03-09 X-dag ordinarie utdelning NSIS B 4.50 DKK
2006-03-02 X-dag ordinarie utdelning NSIS B 4.00 DKK
2005-03-17 X-dag ordinarie utdelning NSIS B 3.50 DKK
2004-03-18 X-dag ordinarie utdelning NSIS B 3.15 DKK
2003-03-20 X-dag ordinarie utdelning NSIS B 2.25 DKK
2002-03-21 X-dag ordinarie utdelning NSIS B 2.00 DKK
2001-03-22 X-dag ordinarie utdelning NSIS B 1.65 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Novonesis är verksamma inom biokemi. Bolaget utvecklar enzymer och mikroorganismer för industriellt bruk. Enzymerna är ett protein som används inom ett flertal olika branscher, huvudsakligen inom jordbruks- och livsmedelsindustrin. Produkterna används inom livsmedel samt kläder, och försäljning innehas på global nivå, med störst närvaro inom Norden och Europa. Bolaget har sitt huvudkontor i Bagsværd.
2021-10-26 13:23:07

Novozymes delivered 7% organic sales growth in the third quarter and 6% organic sales growth in the first nine months of 2021.
Due to stronger performance the company has upgraded its full-year financial guidance from previously 4-6% organic sales growth to 5-6% and an EBIT margin of around 27%, from previously around 26%.

COPENHAGEN, Denmark – October 27, 2021. In the first nine months of the 2021 financial year, Novozymes delivers 6% organic sales growth, an EBIT-margin of 28.8%, and ROIC including goodwill of 22.1%. This marks an important step in fulfilling Novozymes’ long-term growth strategy ‘Unlocking Growth – Powered by Biotech’.

“Our results for the first nine months are strong, and I am proud to say that we deliver double-digit organic sales growth in three of our five business areas. Novozymes is built for growth and we are very pleased to upgrade our full-year outlook to 5-6% organic sales growth. We focus on driving our strategy ‘Unlocking Growth – Powered by Biotech’ forward while executing and delivering on our short-term targets. We continue to deliver good performance, especially in the emerging markets, and I also want to highlight our strong performance in Food & Beverages and Human Health,” says Ester Baiget, President & CEO and continues:

“There is a growing demand for our biological solutions and the investments we’re making now will allow for strong long-term growth and enhanced sustainability impact worldwide. We define our priorities among the available opportunities to maximize the return on investments, while always having a clear sustainability mindset in everything we do. Our results so far clearly show that we are headed in the right direction.”

Novozymes has launched eight products within the first nine months of the year, four of which were launched in the third quarter. The third quarter launches included the game-changing detergent Pristine® for Freshness to the broad markets.

Business area results
For the first nine months of the year, organic performance by business area were 0% in Household Care, 15% in Food, Beverages & Human Health, 12% in Bioenergy, 12% in Grain & Tech Processing, -3% in Agriculture, Animal Health & Nutrition.

While Household Care experienced soft performance in Europe, the business area did see recovery in the third quarter with 3% organic sales growth. The Freshness platform and emerging markets contributed positively and according to expectations.

The decline in Agriculture, Animal Health & Nutrition had been expected and was mainly due to a negative base effect from last year’s DKK ~60 million one-off related to the former BioAg setup. Third-quarter sales grew 16% organically.

Regional results
For the first half of the year, organic growth rates by geography were 2% in Europe, Middle East & Africa, 2% in North America, 12% in Asia Pacific, and 31% in Latin America.

Sales in emerging markets grew 20% organically and developed markets were flat. The strong performance in emerging markets was broad-based with all five business areas growing organically on top of a low-single-digit growth comparator from last year.

Upgraded financial guidance for 2021
Novozymes is now guiding for 5-6% organic sales growth for 2021, with sales in reported DKK roughly on par with the organic sales growth, and an increased EBIT margin from previously ~26% to around 27%. ROIC incl. goodwill is upped and now expected at 20-21% and FCF before acquisitions is upped to DKK 2.8-3.2 billion.

About Novozymes
Novozymes is the world leader in biological solutions. Together with customers, partners, and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel, and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com

NASDAQ OMX: NZYM-B • 6,500 employees • DKK 14,5 billion turnover • 30+ industries • 700+ products

   
Media Relations  
Lina Danstrup,
Head of Media Relations
Phone: +45 30 77 05 52
lind@novozymes.com
  
   
Investor Relations  
Tobias Cornelius Björklund
Head of Investor Relations
Phone: +45 30 77 86 82
tobb@novozymes.com